A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults.

Trial Profile

A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Avibactam/ceftazidime (Primary) ; Ciprofloxacin; Cotrimoxazole; Doripenem
  • Indications Gram-negative infections; Pyelonephritis; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms RECAPTURE-2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Jan 2017 Results from complicated urinary tract infections (cUTI) patients published in an AstraZeneca Media Release
    • 30 Jan 2017 According to AstraZeneca media release, the U.S. Food and Drug Administration (FDA) has approved supplemental New Drug Application (sNDA) to update the label for AVYCAZ (ceftazidime and avibactam) to treat patients with complicated urinary tract infections (cUTI), including pyelonephritis, caused by designated susceptible Gram-negative microorganisms with clinical data from RECAPTURE and REPRISE trials.
    • 14 Jan 2017 Results assessing the In-vitro activity of ceftazidime/avibactam against urinary isolates from patients in two phase III studies (RECAPTURE-1 and RECAPTURE-2; n=1033) published in the Journal of Antimicrobial Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top